Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M W Deininger

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Current Opinion in Hematology|September 25, 1998
Chronic myeloid leukemiaM W Deininger, J M Goldman
Leukemia|April 23, 2004
Ph-positive and -negative myeloproliferative syndromes may co-existM J Mauro, M Loriaux, M W Deininger
Clinical Pharmacology : Advances and Applications|August 3, 2019
Novel approaches to treating advanced systemic mastocytosisJ A Gilreath, L Tchertanov, M W Deininger
Blood|November 9, 2000
The molecular biology of chronic myeloid leukemiaM W Deininger, J M Goldman, J V Melo
Blood|November 14, 1997
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cellsM W Deininger, J M Goldman, N Lydon, et al.
British Journal of Haematology|December 19, 1998
The susceptibility of Philadelphia chromosome positive cells to FAS-mediated apoptosis is not linked to the tyrosine kinase activity of BCR-ABLJ Gora-Tybor, M W Deininger, J M Goldman, et al.
Leukemia|June 13, 2008
Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cellsM MacPartlin, A M Smith, B J Druker, et al.
Leukemia|February 14, 2015
Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1M S Zabriskie, N A Vellore, K C Gantz, et al.
Experimental Hematology|May 17, 2000
The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemiaS B Marley, M W Deininger, R J Davidson, et al.
Cancer Research|April 15, 2000
BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemiaM W Deininger, S Vieira, R Mendiola, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Current Opinion in Hematology|September 25, 1998
Chronic myeloid leukemiaM W Deininger, J M Goldman
Leukemia|April 23, 2004
Ph-positive and -negative myeloproliferative syndromes may co-existM J Mauro, M Loriaux, M W Deininger
Clinical Pharmacology : Advances and Applications|August 3, 2019
Novel approaches to treating advanced systemic mastocytosisJ A Gilreath, L Tchertanov, M W Deininger
Blood|November 9, 2000
The molecular biology of chronic myeloid leukemiaM W Deininger, J M Goldman, J V Melo
Blood|November 14, 1997
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cellsM W Deininger, J M Goldman, N Lydon, et al.
British Journal of Haematology|December 19, 1998
The susceptibility of Philadelphia chromosome positive cells to FAS-mediated apoptosis is not linked to the tyrosine kinase activity of BCR-ABLJ Gora-Tybor, M W Deininger, J M Goldman, et al.
Leukemia|June 13, 2008
Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cellsM MacPartlin, A M Smith, B J Druker, et al.
Leukemia|February 14, 2015
Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1M S Zabriskie, N A Vellore, K C Gantz, et al.
Experimental Hematology|May 17, 2000
The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemiaS B Marley, M W Deininger, R J Davidson, et al.
Cancer Research|April 15, 2000
BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemiaM W Deininger, S Vieira, R Mendiola, et al.
Pageof 4